fbpx

Nyheder

Lundbeckfonden Ventures nyheder

Russell G. Greig Appointed as Chairman of SyntaxinOxford, UK, 6th January 2011: Syntaxin, a biotechnology company developing novel biopharmaceuticals to control cell secretion, today announced Dr Russell G. Greig, Ph. D., has been appointed as Chairman with immediate effect. In joining Syntaxin, Dr. Greig brings with him over 30 years experience in the pharmaceutical industry,...
DBV Technologies closes $25.5 (?19,4) million Series ‘C’ financing round including new investors InnoBio, Lundbeckfond Ventures, Shire plc, and ALTO Invest; as well as existing investors Sofinnova Partners and ALK AbelloProceeds will be used, for the most part, to further continue the clinical development of VIASKIN® Peanut, the world’s first epicutaneous skin patch for desensitization...
Lundbeckfond Ventures is LFÍ Life Science Investments new name
Syntaxin, a biotechnology company developing novel biopharmaceuticals to control cell secretion, announces it has successfully raised £18 million in new funding
Mette Kirstine Agger appointed Head of LFI Life Science Investments
1 64 65 66

Lundbeckfonden Ventures

Nyheder

Enterome initiates first clinical trial with EO2401 – an innovative microbiome-antigen (‘OncoMimic’) based cancer immunotherapy candidate targeting aggressive brain cancer
30. juli 2020
Acacia Pharma Advances Preparations for US Launch of BARHEMSYS® Second API Supplier for BARHEMSYS® Receives FDA Approval
27. juli 2020
Sanifit to start new clinical development program of SNF472 in End Stage Kidney Disease patients with Peripheral Artery Disease
20. juli 2020